Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Auronext Pharma Private Limited, was an unlisted private company incorporated on 02 July, 2009. It is classified as a private limited company and is located in , Telangana. It's authorized share capital was INR 255.00 cr and the total paid-up capital was INR 124.98 cr.
Auronext Pharma's operating revenue range is Under INR 1 cr for the financial year ending on 31 March, 2023. It's book networth has decreased by 1.47%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR lacs. Based on March 2023 numbers.
-1.47%
-0.04%
646.98
1.4
54.0
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(3)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| CS | Venkata Radhakrishna Racharla | <HIDDEN> | 6 years |
| Director | Madan Mohan Reddy Mettu | 01284266 | 4 years |
| Director | Sarath Chandra Reddy Penaka | 01628013 | 15 years |
| Whole-time Director | Jacob Joseph | 08432306 | 4 years |
| Director | Sapna | 08434059 | 6 years |
| CFO | Ravi Kiran Yellapragada | <HIDDEN> | 4 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| AUROBINDO PHARMA LTD |
Active
|
58.1 Cr | 2 | Telangana |
| OREMSI PLASTICS PRIVATE LIMITED |
Strike Off
|
1.3 L | 1 | Telangana |
| CUREPRO PARENTERALS LIMITED |
Amalgamated
|
13.3 Cr | 2 | Telangana |
| THERANYM BIOLOGICS PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| AUROZEST PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| AURO VACCINES PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| CREST EXCIPIENTS LLP |
Strike Off
|
1.3 L | 1 | Telangana |
| EUGIA STERILES PRIVATE LIMITED |
Active
|
44.2 Cr | 1 | Telangana |
| EUGIA PHARMA SPECIALITIES LIMITED |
Active
|
621.0 Cr | 1 | Telangana |
| CURATEQ BIOLOGICS PRIVATE LIMITED |
Active
|
100.0 Cr | 1 | Telangana |
| PRAVESHA INDUSTRIES PRIVATE LIMITED |
Active
|
10.0 Cr | 1 | Telangana |
| EUGIA SEZ PRIVATE LIMITED |
Active
|
4.0 Cr | 1 | Telangana |
| ROSA AVENUES INDIA PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Telangana |
| TRIDENT LIFE SCIENCES LIMITED |
Amalgamated
|
1.6 L | 1 | Telangana |
| AXIS CLINICALS INDIA LIMITED |
Strike Off
|
5.0 L | 1 | Telangana |
| PVR CHEMPHAR PRIVATE LIMITED |
Active
|
2.2 Cr | 1 | Telangana |
| AURYN LABS LIMITED |
Strike Off
|
5.0 L | 1 | Telangana |
| SARATH PENAKA ENTERPRISES LLP |
Active
|
1.0 L | 1 | Telangana |
| AUROBINDO PHARMA FOUNDATION |
Active
|
1.0 L | 1 | Telangana |
| SHREAS INDUSTRIES LIMITED |
Active
|
400.0 Cr | 1 | Telangana |
| SILICON LIFE SCIENCES PRIVATE LIMITED |
Amalgamated
|
110.0 Cr | 3 | Telangana |
| MVIYES PHARMA VENTURES PRIVATE LIMITED |
Active
|
150.2 Cr | 1 | Telangana |
| AUROZYMES LIMITED |
Amalgamated
|
5.0 L | 1 | Telangana |
| SSK LIFESTYLES LIMITED |
Active
|
10.0 Cr | 1 | Telangana |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| SILICON LIFE SCIENCES PRIVATE LIMITED | Telangana | 2008 | ₹ 110.0 Cr |
The incorporation date of AURONEXT PHARMA PRIVATE LIMITED is 02 July, 2009
The authorized share capital of AURONEXT PHARMA PRIVATE LIMITED is INR ₹ 255.0 Cr.
The paid-up capital of AURONEXT PHARMA PRIVATE LIMITED is INR ₹ 125.0 Cr.
The registered address of AURONEXT PHARMA PRIVATE LIMITED is Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1 Hyderabad Knowledge City, Raidurg Panmak tha NA Hyderabad Rangareddi Telangana - 500032
The CIN number of AURONEXT PHARMA PRIVATE LIMITED is U74999TG2009PTC109591.
Expand
Delete
Collapse
See
details
